Lipids and renal cystic disease

Nephrology Dialysis Transplantation

Volumn 25, Issue 11, 2010, Pages 3490-3492

  Schrier, Robert W ^a   Levi, Moshe ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; CYCLIC AMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EVEROLIMUS; GENZ 123346; GLUCOSYLCERAMIDE; GLYCOSPHINGOLIPID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; MAMMALIAN TARGET OF RAPAMYCIN; OCTREOTIDE; PLACEBO; PROTEIN KINASE B; RAPAMYCIN; TOLVAPTAN; UNCLASSIFIED DRUG; WNT PROTEIN; (2 (2',3' DIHYDROBENZO(1,4)DIOXIN 6' YL) 2 HYDROXY 1 PYRROLIDIN 1 YLMETHYLETHYL)NONANOIC ACID AMIDE; (2-(2',3'-DIHYDROBENZO(1,4)DIOXIN-6'-YL)-2-HYDROXY-1-PYRROLIDIN-1-YLMETHYLETHYL)NONANOIC ACID AMIDE; CERAMIDE GLUCOSYLTRANSFERASE; DIOXANE DERIVATIVE; DRUG DERIVATIVE; GLUCOSYLTRANSFERASE; PYRROLIDINE DERIVATIVE;

APOPTOSIS; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; DRUG EFFECT; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; KIDNEY POLYCYSTIC DISEASE; KIDNEY SIZE; MONOTHERAPY; NEPHRONOPHTHISIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ARTICLE; DRUG ANTAGONISM; GLOMERULUS FILTRATION RATE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIOXANES; GLOMERULAR FILTRATION RATE; GLUCOSYLTRANSFERASES; HUMANS; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PYRROLIDINES; SIROLIMUS;

EID: 79952197021     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq545     Document Type: Review

References (20)

1. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007; 369: 1287-1301 (Pubitemid 46552051)
2. Schrier RW, Gross P, Gheorghiade M et al. For the SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099-2112 (Pubitemid 44749318)
3. Torres V. Tolvaptan efficacy and safety in management of polycystic kidney disease and its outcomes. Phase 2 of 4, Clinical Trials Study NCT00413777; phase 3 of 4, Clinical Trials Study NCT00428948. ClinicalTrials.gov (9 August 2010, date last accessed)
4. Hogan MC, Masyuk TV, Page LJ et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney disease and liver disease. J Am Soc Nephrol 2010; 21: 1052-1061
5. Serra A et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363: 820-829
6. Walz G et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363: 830-840
7. Tao Y, Kim J, Faubel S et al. Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease. Proc Natl Acad Sci USA 2005; 102: 6954-6959 (Pubitemid 40675423)
8. Shillingford JM, Murcia NS, Larson C et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 2006; 103: 5466-5471
9. Natoli TA, Smith LA, Rogers KA et al. Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nat Med 2010; 16: 788-792
10. Rani CS, Abe A, Chang Yet al. Cell cycle arrest induced by an inhibitor of glucosylceramide synthase. Correlation with cyclin-dependent kinases. J Biol Chem 1995; 270: 2859-2867
11. Chatterjee S, Shi WY, Wilson P et al. Role of lactosylceramide and MAP kinase in the proliferation of proximal tubular cells in human polycystic kidney disease. J Lipid Res 1966; 37: 1334-1344
12. Lahiri S, Futuerman AH. The metabolism and function of sphingolipids and glycosphingolipids. Cell Mol Life Sci 2007; 64: 2270-2284 (Pubitemid 47347954)
13. Lukina E et al. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood 2010; 116: 893-899
14. Cadnapaphornchai M, Schrier RW. Effect of statin therapy on disease progression in autosomal dominant polycystic kidney disease (ADPKD). Clinical Trials Study NCT00456365. ClinicalTrials.gov (9 August 2010, date last accessed)
15. Cadnapaphornchai M, McFann K, Strain J et al. Prospective change in renal volume and function in children with ADPKD. Clin J Am Soc Nephrol 2009; 4: 820-829
16. Perrone RD, Ruthazer R, Terrin NC. Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: Contribution of extrarenal complications to mortality. Am J Kidney Dis 2001; 38: 777-784
17. Chapman A et al. The HALT polycystic kidney disease trials: Design and implementation. Clin J Am Soc Nephrol 2010; 5: 102-109
18. Chapman AB, Johnson A, Gabow PA et al. The renin-angiotensin- aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med 1990; 323: 1091-1096 (Pubitemid 20370729)
19. Loghman-Adham M, Soto CE, Inagami T et al. The intrarenal reninangiotensin system in autosomal dominant polycystic kidney disease. Am J Physiol Renal Physiol 2004; 287: F775-F788 (Pubitemid 39280514)
20. Schrier RW, McFann K, Johnson A et al. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomaldominant polycystic kidney disease: Results of a seven-year prospective randomized study. J Am Soc Nephrol 2002; 13: 1733-1739 (Pubitemid 34700597)